Eeyarestatin I - CAS:412960-54-4

您当前的位置：

Eeyarestatin I

目录号 : KM10620 CAS No. : 412960-54-4 纯度 : 98%

Data Sheet 产品使用指南

Eeyarestatin I 是一种有效的内质网相关蛋白降解 (ERAD) 抑制剂，是一种有效的蛋白易位抑制剂。Eeyarestatin I 靶向与 p97 相关的去泛素化过程 (PAD)，并抑制依赖于 atx3 的去泛素化。Eeyarestatin I 通过促凋亡蛋白 NOXA 诱导细胞死亡，并具有抗癌作用。

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide B In-stock
Isoginkgetin In-stock
Ginkgolic acid C17:1 In-stock
Ginkgolic Acid In-stock
Propargyl-PEG4-amine In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects.

体外研究

Eeyarestatin I (2.5-40 μM; 48 hours; A549 and H358 cells) treatment causes a dose-dependent cell death of both A549 and H358 cells.
Eeyarestatin I (2.5-40 μM; 48 hours; A549 and H358 cells) treatment increases endoplasmic reticulum (ER) stress markers including Bip and CHOP as low as 20 μM. Eeyarestatin I treatment shows a dose dependent ubiquitination of key proteins including PERK and IRE1α.
Eeyarestatin I (20 μM; 48 hours; A549 and H358 cells) treatment induces cell migration and cell invasion.
Eeyarestatin 1 prevents the transfer of nascent proteins from the membrane-targeting complex to the ER translocation machinery, most probably by inactivating the Sec61 complex.

Cell Viability Assay

Cell Line:	A549 and H358 cells
Concentration:	2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:	48 hours
Result:	Caused dose dependent cell death of both A549 and H358 cells.

Western Blot Analysis

Cell Line:	A549 and H358 cells
Concentration:	2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:	48 hours
Result:	Increased ER stress markers including Bip and CHOP.

分子式

C₂₇H₂₅Cl₂N₇O₇

分子量

630.44

CAS号

412960-54-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

DMSO : 25 mg/mL (39.65 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5862 mL	7.9310 mL	15.8619 mL
5 mM	0.3172 mL	1.5862 mL	3.1724 mL
10 mM	0.1586 mL	0.7931 mL	1.5862 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.25 mg/mL (1.98 mM); Suspended solution; Need ultrasonic

此方案可获得 1.25 mg/mL (1.98 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。